Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Se Ik | - |
dc.contributor.author | Song, Minsun | - |
dc.contributor.author | Hwangbo, Suhyun | - |
dc.contributor.author | Lee, Sungyoung | - |
dc.contributor.author | Cho, Untack | - |
dc.contributor.author | Kim, Ju-Hyun | - |
dc.contributor.author | Lee, Maria | - |
dc.contributor.author | Kim, Hee Seung | - |
dc.contributor.author | Chung, Hyun Hoon | - |
dc.contributor.author | Suh, Dae-Shik | - |
dc.contributor.author | Park, Taesung | - |
dc.contributor.author | Song, Yong-Sang | - |
dc.date.available | 2021-02-22T05:46:21Z | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.issn | 2005-9256 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/2947 | - |
dc.description.abstract | Purpose Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC. Materials and Methods We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients' clinicopathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied. Results The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively. Conclusion We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.title | Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4143/crt.2018.508 | - |
dc.identifier.scopusid | 2-s2.0-85069159781 | - |
dc.identifier.wosid | 000476707300030 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.51, no.3, pp 1144 - 1155 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 51 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1144 | - |
dc.citation.endPage | 1155 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002486723 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | PROGRESSION-FREE SURVIVAL | - |
dc.subject.keywordPlus | PRIMARY PERITONEAL | - |
dc.subject.keywordPlus | PRIMARY SURGERY | - |
dc.subject.keywordPlus | FALLOPIAN-TUBE | - |
dc.subject.keywordPlus | ADVANCED-STAGE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordAuthor | Ovarian neoplasms | - |
dc.subject.keywordAuthor | Ovarian epithelial cancer | - |
dc.subject.keywordAuthor | Nomograms | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Treatment response | - |
dc.subject.keywordAuthor | Survival outcomes | - |
dc.identifier.url | https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2018.508 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.